SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 6, 2021
app pub date -
Aug 27, 2020
filing date -
Aug 27, 2019
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure provides modified immune cells or precursors thereof (e.g. T cells) comprising chimeric antigen receptors (CARs) capable of binding human IL13Rα2. Also provided are bispecific CARs, parallel CARs, tandem CARs, BiTEs, BiTE/CARs, and BiTE/BiTEs. Compositions and methods of treatment are also provided.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully